Establishment of PDX model of oral cancer and PDX-derived cell lines, and usefulness of anti-HER2 antibody therapy

被引：0
|
作者：
Seki, Yuki [1 ]
Kariya, Ryusho [2 ]
Yoshida, Ryoji [3 ]
Kawahara, Kenta [3 ]
Hirayama, Masatoshi [3 ]
Takahashi, Nozomu [3 ]
Nakamoto, Masafumi [3 ]
Takeshita, Hisashi [3 ]
Okada, Seiji [2 ]
Nakayama, Hideki [3 ]
机构：
[1] Kumamomto Univ, Grad Sch Med Sci, Kumamoto, Japan
[2] Kumamoto Univ, Div Hematopoiesis, Joint Res Ctr Human Retrovirus Infect, Kumamoto, Japan
[3] Kumamoto Univ, Dept Oral & Maxillofac Surg, Fac Life Sci, Kumamoto, Japan
来源：
CANCER SCIENCE | 2024年 / 115卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-2325
引用
收藏
页码：1074 / 1074
页数：1
相关论文
共 50 条
  • [41] Modelling of pancreatic cancer biology: transcriptomic signature for 3D PDX-derived organoids and primary cell line organoid development
    Shannon R. Nelson
    Chenxi Zhang
    Sandra Roche
    Fiona O’Neill
    Niall Swan
    Yonglun Luo
    AnneMarie Larkin
    John Crown
    Naomi Walsh
    Scientific Reports, 10
  • [42] Anti-HER2 antibody therapy using gene-transduced adipocytes for HER2-positive breast cancer
    Masuda, Takahito
    Fujimoto, Hiroshi
    Teranaka, Ryotaro
    Kuroda, Masayuki
    Aoyagi, Yasuyuki
    Nagashima, Takeshi
    Sangai, Takafumi
    Takada, Mamoru
    Nakagawa, Ayako
    Kubota, Yoshitaka
    Yokote, Koutaro
    Ohtsuka, Masayuki
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 180 (03) : 625 - 634
  • [43] The tumor immunosuppressive microenvironment impairs the therapy of anti-HER2/neu antibody
    Xu, Meng
    Du, Xuexiang
    Liu, Mingyue
    Li, Sirui
    Li, Xiaozhu
    Fu, Yang-Xin
    Wang, Shengdian
    PROTEIN & CELL, 2012, 3 (06) : 441 - 449
  • [44] Developing Model Systems of Neuroendocrine Tumors: Cell Lines and Patient-Derived Xenograft (PDX) Tumors
    Kaemmer, Courtney
    Howe, James
    Galbraith, Joseph
    Knudson, C. Michael
    Darbro, Benjamin
    Milosavljevic, Tanja
    Woltering, Eugene
    Wen, Kuo-Kuang
    Wu, Meng
    Quelle, Dawn
    PANCREAS, 2018, 47 (03) : 343 - 343
  • [45] The tumor immunosuppressive microenvironment impairs the therapy of anti-HER2/neu antibody
    Meng Xu
    Xuexiang Du
    Mingyue Liu
    Sirui Li
    Xiaozhu Li
    YangXin Fu
    Shengdian Wang
    Protein & Cell, 2012, 3 (06) : 441 - 449
  • [46] Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model
    Matsui, Y
    Inomata, M
    Tojigamori, M
    Sonoda, K
    Shiraishi, N
    Kitano, S
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2005, 27 (03) : 681 - 685
  • [47] A new ER+Her2- Palbociclib resistant breast cancer PDX model.
    Melton, Michele
    Hyddmark, Emma M.
    Jiang, Hongmei
    Bast, Athena
    Semanik, Nicole
    Deeds, Stacy
    Brown, Andrew
    CANCER RESEARCH, 2021, 81 (13)
  • [48] Trastuzumab, a humanized anti-HER2 monoclonal antibody, for the treatment of breast cancer
    Albanell, J
    Baselga, J
    DRUGS OF TODAY, 1999, 35 (12): : 931 - 946
  • [49] Anti-HER2 vaccines: new prospects for breast cancer therapy
    Maha Zohra Ladjemi
    William Jacot
    Thierry Chardès
    André Pèlegrin
    Isabelle Navarro-Teulon
    Cancer Immunology, Immunotherapy, 2010, 59 : 1295 - 1312
  • [50] Decreased HER2 expression in endometrial cancer following anti-HER2 therapy
    Chui, M. Herman
    Brown, David N.
    Paula, Arnaud Da Cruz
    da Silva, Edaise M.
    Momeni-Boroujeni, Amir
    Reis-Filho, Jorge S.
    Zhang, Yanming
    Makker, Vicky
    Ellenson, Lora Hedrick
    Weigelt, Britta
    JOURNAL OF PATHOLOGY, 2024, 262 (02): : 129 - 136
12345